Moreover, anti-TNF inhibitor etanercept is ineffective for IBD (41), and patients with PsA treated with the etanercept had a significant increase in the risk of developing CD [adjusted HR, 2.0 (95% CI, 0.8–2.2)] or UC [2.0 (1.5–2.8)] (42). Here, TNF is linked to inflammatory bowel disease.